Cargando…

Relapsed focal segmental glomerulosclerosis and severe acute kidney injury after Oxford-AstraZeneca (AZ) COVID-19 vaccine

Detalles Bibliográficos
Autores principales:	Huang, Yu-Ting, Chang, Fu-Pang, Hung, Szu-Chun, Wang, Yi-Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710270/ https://www.ncbi.nlm.nih.gov/pubmed/36457964 http://dx.doi.org/10.5114/aoms/153477

Ejemplares similares

Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021)

Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
por: Cross, Samuel, et al.
Publicado: (2021)

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
por: Alhammad, Norah S, et al.
Publicado: (2022)

Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers
por: Chau, Nguyen Van Vinh, et al.
Publicado: (2022)

Et de trois : l’UE recommande le vaccin AstraZeneca/Oxford
por: Manus, Jean-Marie
Publicado: (2021)

Le vaccin AstraZeneca-Oxford sur le bureau de l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Monoarthritis induced by the Oxford-AstraZeneca(R) SARS-CoV-2 vaccine
por: Schoenardie, Bruna Ossanai, et al.
Publicado: (2022)

Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia
por: Garnier, Matthieu, et al.
Publicado: (2021)

Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
por: Katsouli, Olga K., et al.
Publicado: (2023)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine
Publicado: (2021)

COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine
Publicado: (2021)

Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination
por: Permezel, Fiona, et al.
Publicado: (2021)

Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two
por: Razzaq, Azhar Kareem, et al.
Publicado: (2021)

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine
por: Al‐Ahmad, Mona, et al.
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign
por: Vallée, A., et al.
Publicado: (2021)

Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine
por: Morlidge, Clare, et al.
Publicado: (2021)

AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021)

Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

AstraZeneca COVID-19 vaccine-related thromboembolism
Publicado: (2021)

Bleeding and clotting with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

AstraZeneca COVID-19 vaccine: no increased rate of VTE
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
por: Agharbi, F.-Z., et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
Publicado: (2021)

Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021)

AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
Publicado: (2021)

Ischemic stroke after AstraZeneca (Covid-19) vaccination
por: Alammar, Muath A.
Publicado: (2021)

Lipschütz ulcers after AstraZeneca COVID-19 vaccination()
por: Bracho-Borro, Maria, et al.
Publicado: (2023)

Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen
por: Soltani Hekmat, Ava, et al.
Publicado: (2021)

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
por: Teh, Natalie, et al.
Publicado: (2021)

The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis
por: Jain, Vageesh, et al.
Publicado: (2022)

Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report
por: Leclerc, Simon, et al.
Publicado: (2021)

Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries
por: Sharun, Khan, et al.
Publicado: (2021)

Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford–AstraZeneca) Vaccination
por: Ali, Azhar, et al.
Publicado: (2022)

Chronic Spontaneous Urticaria Triggered by the AstraZeneca/Oxford COVID-19 Vaccine with Achieved Remission: A Case Report
por: Brooks, Stephanie G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ji0aq1mb52rnn178p6g3ffccju